Appointments at Millipore, AM Technology and Alder Pharmaceuticals – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Vice president Management occupations Pharmacology

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Millipore, AM Technology and Alder Pharmaceuticals.

Millipore​ has promoted John Sweeney​ as vice president of its life science business unit. Sweeney joined Millipore in 2003 and most recently worked as vice president (VP) of strategy and marketing services.

Alder Pharmaceuticals ​has appointed Mark Young​ as senior VP of pharmaceutical operations. Young has more than 30 years in process development and manufacturing of biologics produced from yeast, bacteria and mammalian cells.

This experience, and his expertise in technology transfer and clinical development, was gained at numerous biotechs, including Zymogenetics, Biomira and Synergen.

AM Technology​ has appointed Rolf Dahlbeck​ as its agent in Germany, Switzerland and Austria for its Coflore flow reactor products.

The appointment of Dahlbeck, who more than 20 years experience in this field has a strong knowledge of flow chemistry, is intended to improve customer support in the Swiss, German and Austrian markets.

Nancy Wysenski ​has resigned as CEO of Endo Pharmaceuticals​ to attend to family matters. Endo is looking for a new CEO using an executive search firm.

Mark Goldsmith​ has been appointed as CEO of Constellation Pharmaceuticals​. Goldsmith joins the company from Prospect Venture Partners and he was also cofounder and CEO of Cogentus Pharmaceuticals.

In addition Constellation has raised $17.2m (€12.1m) in venture capital that it will use to enhance its R&D capabilities and accelerated development of its preclinical pipeline.

BioTime​ has appointed Walter Funk​ as VP for stem cell research. Funk has previously worked at Geron, Nuvelo and was co-founder of Parallax Venture Partners.

Ruhi Kahn ​has been named as VP, business development at Acorda Therapeutics​. Kahn joined Acorda as executive director, business development and has previously worked at Lexicon and Fidelity Biosciences.

Related topics Markets & Regulations

Related news